The role of HOXB4 in myelofibrosis and new therapy targeting USF

• Project/Area Number: 23591397
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: University of Miyazaki
• Principal Investigator: SHIMODA KAZUYA 宮崎大学, 医学部, 教授 (90311844)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: JAK2 / TET2 / MPN / HSC / PMF / USF1/2 / JAk2

Research Abstract

We examined the gene expression patterns of Lineage-Sca1+ BM cells in JAK2V617F transgenic mice that developed myelofibrosis, and found that HOXB4 and TGF-b1, the target genes of transcriptional factor USF1, were highly expressed. The transcriptional activity of USF1 is up-regulated by thrombopoietin stimulation or JAK2 V617F via activation of MAPK.
Somatic loss-of-function mutations of TET2 are frequently observed in patients with myeloproliferative neoplasams. Mice with low TET2 exhibited only mild monocytosis, splenomegaly, and extramedullary hematopoiesis compared to wild type mice. HSCs from TET2 low mice exhibit increased self-renewal ability in vivo. In competitive transplantation assays, HSCs from TET2 low mice possess a competitive growth advantage over wild type HSCs. These data indicate that TET2 plays a critical role in HSC homeostasis.

Research Products

• [Journal Article] Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms (2014)
  • Author(s): Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K
  • Journal Title: Blood Cancer J Volume: 4
  • Peer Reviewed
• [Journal Article] 本邦における原発性骨髄線維症の臨床像 (2014)
  • Author(s): 下田和哉、竹中克斗、北中明、赤司浩一
  • Journal Title: 臨床血液 Volume: 55(3) Pages: 289-294
  • NAID: 130004724847
• [Journal Article] Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. (2014)
  • Author(s): Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K.
  • Journal Title: Blood Cancer J Volume: 4 Issue: 1 Pages: e174-e174
  • DOI: 10.1038/bcj.2013.73
  • Peer Reviewed
• [Journal Article] Contribution of bone marrow-derived hematopoietic stem/progenitor cells to the generation of donor-marker+ cardiomyocytes in vivo (2013)
  • Author(s): Fukata M, Ishikawa F, Najima Y, Yamauchi T, Saito Y, Takenaka K, Miyawaki K, Shimazu H, Shimoda K, Kanemaru T, Nakamura K, Odashiro K, Nagafuji K, Harada M, Akashi K
  • Journal Title: PLoS One Volume: 8(5)
  • Peer Reviewed
• [Journal Article] Concurrent of Ezh2 and Tet2 cooperates in the Pathogenesis of myelodysplastic disorders (2013)
  • Author(s): Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A
  • Journal Title: J.Exp.Med Volume: 210(12) Pages: 2627-2639
  • Peer Reviewed
• [Journal Article] 骨髄増殖性腫瘍の分子機構と新規薬物療法 (2013)
  • Author(s): 北中明、幣光太郎、下田和哉
  • Journal Title: 臨床血液 Volume: 54(10) Pages: 151-157
  • NAID: 10031196313
• [Journal Article] Contribution of bone marrow-derived hematopoietic stem/progenitor cells to the generation of donor-marker+ cardiomyocytes in vivo. (2013)
  • Author(s): Fukata M, Ishikawa F, Najima Y, Yamauchi T, Saito Y, Takenaka K, Miyawaki K, Shimazu H, Shimoda K, Kanemaru T, Nakamura K, Odashiro K, Nagafuji K, Harada M, Akashi K
  • Journal Title: PLoS One. Volume: 8
  • Peer Reviewed
• [Journal Article] Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. (2013)
  • Author(s): Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A.
  • Journal Title: The Journal of Experimental Medicine Volume: 210(12) Issue: 12 Pages: 2627-39
  • DOI: 10.1084/jem.20131144
  • Peer Reviewed
• [Journal Article] Elevated HIF-1αexpression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy (2012)
  • Author(s): Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, Kamiunten A, Sekine M, Taniguchi Y, Yamamoto S, Hidaka T, Katayose K, Kubuki Y, Dobashi H, Bandoh S, Ohnishi H, Fukai F, Shimoda K
  • Journal Title: Leuk Res Volume: 36
  • Peer Reviewed
• [Journal Article] Acute myeloid leukemia in clinical practice : a retrospective population-based cohort study in Miyazaki Prefecture, Japan (2012)
  • Author(s): Matsunaga T, Yamashita K, Kubuki Y, Toyama T, Imataki O, Maeda K, Kawano N, Satou S, Kawano H, Ishizaki J, Yoshida S, Kameda T, Sasaki T, Sekine M, Kamiunten A, Taniguchi Y, Hidaka T, Katayose K, K-Shimoda H, Shide K, Yamamoto S, Moritake H, Nunoi H, Makino S, Kitanaka A, Matsuoka H, Shimoda K
  • Journal Title: Int J Hematol Volume: 96 Pages: 342-349
  • NAID: 10031121262
  • Peer Reviewed
• [Journal Article] Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation (2012)
  • Author(s): Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M,Yamamoto S, Hidaka T, Kubuki Y, Yokokura S, Uemura M, Matsuoka A, Waki F, Matsumoto K, Kanaji N, Ishii T, Imataki O, Dobashi H, Bandoh S, Shimoda K
  • Journal Title: Ann Hematol Volume: 91 Pages: 1633-1643
  • Peer Reviewed
• [Journal Article] Clinical significance of CADM1/TSLC1/IgSF4 expression in Adult T-cell leukemia/ ymphoma (2012)
  • Author(s): Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K
  • Journal Title: Leukemia Volume: 26 Pages: 1238-1246
  • Peer Reviewed
• [Journal Article] TET2 is essential for survival and hematopoietic stem cell homeostasis (2012)
  • Author(s): Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K
  • Journal Title: Leukemia. Leukemia Volume: 26 Pages: 2216-2223
  • Peer Reviewed
• [Journal Article] Tyk2 and stat3 regulate brown adipose tissue differentiation and obesity (2012)
  • Author(s): Derecka M, Gornicka A, Koralov SB, Szczepanek K, Morgan M, Raje V, Sisler J, Zhang Q, Otero D, Cichy J, Rajewsky K, Shimoda K, Poli V, Strobl B, Pellegrini S,Hamis TE, Seale P, Russell AP, McAinch AJ, O'Brien PE, Keller SR, Croniger CM, Kordula T, Lamer AC
  • Journal Title: Cell Metabolism Volume: 16 Pages: 814-82
  • Peer Reviewed
• [Journal Article] TET2 is essential for survival and hematopoietic stem cell homeostasis (2012)
  • Author(s): 幣光太郎
  • Journal Title: Leukemia Volume: (印刷中) Issue: 10 Pages: 2216-2223
  • DOI: 10.1038/leu.2012.94
  • Peer Reviewed
• [Journal Article] Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy (2012)
  • Author(s): 松永卓也
  • Journal Title: Leukemia Research Volume: (印刷中) Issue: 6 Pages: 122-124
  • DOI: 10.1016/j.leukres.2012.02.028
  • Peer Reviewed
• [Journal Article] Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation. (2012)
  • Author(s): Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M, Ｙａｍａｍｏｔｏ S, Shimoda K, 他12名
  • Journal Title: Ann Hematol Volume: 91 Issue: 10 Pages: 1633-1643
  • DOI: 10.1007/s00277-012-1498-y
  • Peer Reviewed
• [Journal Article] Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma (2012)
  • Author(s): Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K
  • Journal Title: Leukemia Volume: Jan;26 (6) Issue: 6 Pages: 1238-46
  • DOI: 10.1038/leu.2011.379
  • Peer Reviewed
• [Journal Article] Tyk2 and stat3 regulate brown adipose tissue differentiation and obesity. (2012)
  • Author(s): Derecka M, Gornicka A, Koralov SB, Szczepanek K, Morgan M, Raje V, Sisler J, Zhang Q, Otero D, Shimoda K, 他14名
  • Journal Title: Cell Metabolism Volume: 16 Issue: 6 Pages: 814-824
  • DOI: 10.1016/j.cmet.2012.11.005
  • Peer Reviewed
• [Journal Article] Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. (2012)
  • Author(s): Matsunaga T, Yamashita K, Kubuki Y, Toyama T, Imataki O, Maeda K, Kawano N, Satou S, Kawano H, Shimoda K, 他17名
  • Journal Title: Int J Hematol Volume: 96 Issue: 3 Pages: 342-349
  • DOI: 10.1007/s12185-012-1146-2
  • NAID: 10031121262
  • Peer Reviewed
• [Journal Article] Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture (2012)
  • Author(s): 河野徳明
  • Journal Title: International Journal of Clinical Oncology Volume: (印刷中) Issue: 4 Pages: 336-340
  • DOI: 10.1007/s10147-011-0292-5
  • Peer Reviewed
• [Journal Article] Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C (2012)
  • Author(s): Imakiire K, Uto H, Sato Y, Sasaki F, Mawatari S, Ido A, Shimoda K, Hayashi K, Stuver SO, Ito Y, Okanoue T, Tsubouchi H
  • Journal Title: Mol Med Rep Volume: 6(2) Pages: 259-64
  • DOI: 10.3892/mmr.2012.924
  • Peer Reviewed
• [Journal Article] R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasma (2011)
  • Author(s): Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlim J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Tomeros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K
  • Journal Title: Blood Volume: 117 Pages: 6866-6875
  • Peer Reviewed
• [Journal Article] Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms (2011)
  • Author(s): Nakaya Y, Shide K, Niwa T, Homan J, Sugahara S, Horio T, Kuramoto K, Kotera T, Shibayama H, Hori K, Naito H, Shimoda K
  • Journal Title: Blood Cancer J Volume: 1, (published online)
  • Peer Reviewed
• [Journal Article] 骨髄増殖性疾患分子病態と治療 (2011)
  • Author(s): 下田晴子、下田和哉
  • Journal Title: 血液内科 Volume: 62(5) Pages: 648-655
• [Journal Article] 血小板増加症 (2011)
  • Author(s): 上運天綾子、下田和哉
  • Journal Title: 診断と治療 Volume: 99(7) Pages: 1143-1147
• [Journal Article] 骨髄増殖性腫瘍とJAK2変異 (2011)
  • Author(s): 関根雅明、下田和哉
  • Journal Title: 日本検査血液学雑誌 Volume: 12(2) Pages: 224-229
• [Journal Article] R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasma. (2011)
  • Author(s): Shide K
  • Journal Title: Blood Volume: 117 Pages: 6866-6875
  • Peer Reviewed
• [Journal Article] Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. (2011)
  • Author(s): Peng DJ
  • Journal Title: J Immunol. Volume: 186 Pages: 5638-5647
  • Peer Reviewed
• [Presentation] Impact of TET2 deficiency on ^のN harboring JAK2V617F mutation (2013)
  • Author(s): Kameda T, Shide K, Sekine M, Kamiunten A,Hidaka T, Kubuki Y, Kameda T, Kitanaka A,Shimoda K, MP Marutsuka K
  • Organizer: 第55回ASH Annual Meeting and Exposition
  • Place of Presentation: New Orleans
  • Year and Date: 2013-12-09
• [Presentation] Japanese survey of myelofibrosis (2013)
  • Author(s): 下田和哉
  • Organizer: 第75回日本血液学会学術集会、Asian Joint Symposium
  • Place of Presentation: 札幌
  • Year and Date: 2013-10-13
• [Presentation] Development of new therapies for myelofiborosis(MF) that target the transcription factor USF1 (2013)
  • Author(s): Shide K, Kameda T, Shimoda H, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Kameda T, Kitanaka A,Shimoda K
  • Organizer: 第75回日本血液学会学術集会
  • Place of Presentation: 札幌
  • Year and Date: 2013-10-12
• [Presentation] The impact of TET2 deficiency on MPN induced by JAK2V617F mutation (2013)
  • Author(s): Kameda T, Shide K, Sekine M, Kamiunten A,Hidaka T, Kubuki Y, Kameda T, Kitanaka A,Shimoda K, Marutsuka K
  • Organizer: 第75回日本血液学会学術集会
  • Place of Presentation: 札幌
  • Year and Date: 2013-10-12
• [Presentation] Concurrent depletion of Ezh2 and Tet2 accelerates development of myelodysplastic disorders in mice (2013)
  • Author(s): Muto T,Sashida G, Oshima M, Wendt G, Kashio MM, Nagata Y, Sanada M, Miyagi S,Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A
  • Organizer: 第75回日本血液学会学術集会
  • Place of Presentation: 札幌
  • Year and Date: 2013-10-12
• [Presentation] 骨髄増殖性腫瘍の分子機構と新規薬物療法 (2013)
  • Author(s): 下田和哉
  • Organizer: 第75回日本血液学会学術集会教育講演
  • Place of Presentation: 札幌
  • Year and Date: 2013-10-11
• [Presentation] Japanese survey of myelofibrosis (2013)
  • Author(s): 下田和哉
  • Organizer: 第75回日本血液学会学術集会Asian Joint Symposium
  • Place of Presentation: 札幌
• [Presentation] 骨髄増殖性腫瘍の分子機構と新規薬物療法 (2013)
  • Author(s): 下田和哉
  • Organizer: 第75回日本血液学会学術集会
  • Place of Presentation: 札幌
• [Presentation] Impact of TET2 deficiency on MPN harboring JAK2V617F mutation (2013)
  • Author(s): Kameda T, Shide K, Sekine M, Kamiunten A,Hidaka T, Kubuki Y, Kameda T, Kitanaka A,Shimoda K, Marutsuka K
  • Organizer: 第55回ASH Annual Meeting and Exposition
  • Place of Presentation: New Orleans
• [Presentation] Cooperation of JAK2V617F and CBFb-MYH11 is insufficient for leukemic transformation of mouse MPNs (2012)
  • Author(s): Kameda T, Shide K, Shimoda H, Kamiunten A, Hidaka T, Katayose K, Kubuki Y, Kitanaka A, Shimoda K, Marutsuka K
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-20
• [Presentation] JAK2阻害薬によるMPNの治療 (2012)
  • Author(s): 幣光太郎
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-19
• [Presentation] TET2 is essential for survival and hematopoietic stem cell homeostasis (2012)
  • Author(s): Shide K, Kameda T, Shimoda H, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Marutsuka K, Iwama A, Kitanaka A, Shimoda K
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-19
• [Presentation] TET2 is essential for survival and hematopoietic stem cell homeostasis. (2012)
  • Author(s): Shide K, Kameda T,Shimoda H,Kamiunten A,SekineM,Hidaka T,Kubu ki Y,Marutsuka K, Iwama A, Kitanaka A, Shimoda K
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
• [Presentation] Cooperation of JAK2V617F and CBFb-MYH11 is insufficient for leukemic transformation of mouse MPNs. (2012)
  • Author(s): Kameda T,Shide K,ShimodaH, Kamiunten A, Hidaka T, Katayose K,Kubuki Y,Yoko K, Kitanaka A, Shimoda K, Marutsuka K
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
• [Presentation] TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation (2011)
  • Author(s): Shide K, Kameda T, Shimoda H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Kitanaka A, Shimoda K
  • Organizer: 第American Society of Hematology 53th Annual Meeting
  • Place of Presentation: サンディエゴ
  • Year and Date: 2011-12-10
• [Presentation] NS-018, a potent novel JAK2 inhibitor, effectively treats murine MPN induced by JAK2V617F mutant (2011)
  • Author(s): Shide K,Nakaya Y, Kameda T, Shimoda H, Hidaka T, Katayose K, Kubuki Y, Matsunaga T, Homan J, Kotere T, Shibayama H, Naito H, Shimoda K
  • Organizer: 第73回日本血液学会学術集会
  • Place of Presentation: 名古屋
  • Year and Date: 2011-10-15
• [Presentation] Selective and preferential inhibition of an activated form of JAK2 by a novel JAK2 inhibitor, NS-018 (2011)
  • Author(s): Nakaya Y,Shide K, Niwa T, Horio T, Homan J, Sugahara S, Kuramoto K, Hori K, Naito H, Shimoda K
  • Organizer: 第73回日本血液学会学術集会
  • Place of Presentation: 名古屋
  • Year and Date: 2011-10-15
• [Presentation] Clinical management of primary myelofibrosis patients (2011)
  • Author(s): Shimoda K
  • Organizer: 第2回日本血液学会国際シンポジウム
  • Place of Presentation: 長崎
  • Year and Date: 2011-04-24
• [Presentation] NS-018, a potent novel JAK2 inhibitor, effectively treats murine MPN induced by JAK2V617F mutant (2011)
  • Author(s): Shide K
  • Organizer: 第73回日本血液学会
  • Place of Presentation: 名古屋
• [Presentation] TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation (2011)
  • Author(s): Shide K
  • Organizer: American Society of Hematology 53th Annual Meeting,
  • Place of Presentation: San Diego CA
• [Book] 骨髄増殖性腫瘍に対する分子標的治療,血液疾患最新の治療2014-2016,24-29 (2014)
  • Author(s): 上運天綾子,下田和哉, (直江知樹,小澤敬也,中尾眞二編)
  • Publisher: 南江堂, (東京)
• [Book] 骨髄線維症に対するJAK阻害薬.Annual Review血液2014 (2014)
  • Author(s): 幣光太郎,下田和哉, (高久史麿、小澤敬也,坂田洋一,金倉譲,小島勢二編)
  • Publisher: 中外医学社
• [Book] 血液疾患最新の治療 (2014)
  • Author(s): 上運天綾子,下田和哉
  • Total Pages: 6
  • Publisher: 南江堂
• [Book] Annual Review 血液 201４ (2014)
  • Author(s): 幣光太郎, 下田和哉
  • Total Pages: 7
  • Publisher: 中外医学社
• [Book] 骨髄線維症内科学書 (2013)
  • Author(s): 下田和哉, (小川聡総編)
  • Publisher: 中山書店, (東京)
• [Book] 慢性骨髄性白血病/骨髄増殖性腫瘍(Chronic myelogenous leukemia : CML/ myeloproliferative neoplasms : MPN)造血器腫瘍診療ガイドライン2013年版, (日本血液学会編) (2013)
  • Author(s): 薄井紀子,木崎昌弘,下田和哉,高橋直人
  • Publisher: 金倉出版
• [Book] 骨髄線維症,ここまできた白血病/MDS治療 (2013)
  • Author(s): 亀田拓郎,下田和哉, (金倉謙総編)
  • Publisher: 中山書店
• [Book] 内科学書 (2013)
  • Author(s): 下田和哉
  • Total Pages: 4
  • Publisher: 中山書店
• [Book] 造血器腫瘍診療ガイドライン2013年版 (2013)
  • Author(s): 薄井紀子,木崎昌弘,下田和哉,高橋直人
  • Total Pages: 28
  • Publisher: 金倉出版
• [Book] 治療 (2013)
  • Author(s): 亀田拓郎,下田和哉
  • Total Pages: 6
  • Publisher: 中山書店
• [Book] 真性赤血球増加症,本態性血小板血症,原発性骨髄線維症.今日の治療指針2012年版私はこう治療している (2012)
  • Author(s): 下田和哉, (山口徹,北原光夫,福井次夫編)
  • Publisher: 金原出版社
• [Book] 骨髄線維症に対する新規治療薬.Annual Review血液2012 (2012)
  • Author(s): 北中明,下田和哉, (高久史麿、小澤敬也、坂田洋一、金倉譲、小島勢二編)
  • Publisher: 中外医学社
• [Book] MPNに対する分子標的療法の可能性. EBM血液疾患の治療 (2012)
  • Author(s): 亀田拓郎,下田和哉, (金倉譲,木崎昌弘,鈴木律朗,神田善伸)
  • Publisher: 中外医学社
• [Book] 慢性骨髄性白血病・骨髄増殖性腫瘍.新臨床腫瘍学(改訂第3版)がん薬物療法専門医のために.日本臨床腫瘍学会編 (2012)
  • Author(s): 下田和哉
  • Publisher: (株)南江堂
• [Book] 骨髄系骨髄増殖性腫瘍のモデル動物を用いた解析. Annual Review血液2013 (2012)
  • Author(s): 幣光太郎,下田和哉, (高久史麿,小澤敬也,坂田洋一,金倉譲,小島勢二編)
  • Publisher: 中外医学社
• [Book] Annual Review 血液２０１２ (2012)
  • Author(s): 北中明、下田和哉
  • Total Pages: 266
  • Publisher: 中外医学社
• [Book] 今日の治療指針２０２１年版私はこうして治療している (2012)
  • Author(s): 下田和哉
  • Total Pages: 2064
  • Publisher: 金原出版社
• [Book] 原発性骨髄線維症,血液専門医テキスト,日本血液学会編(ア) (2011)
  • Author(s): 幣光太郎,下田和哉
  • Publisher: 南江堂
• [Book] 原発性骨髄線維症,専門医のための薬物療法Q&A血液,編 (2011)
  • Author(s): 谷口康博,下田和哉
  • Publisher: 中外医学社
• [Book] 骨髄線維症,難治性貧血診療ガイド-特発性造血障害の病態・診断・治療の最新動向,難治性貧血診療ガイド (2011)
  • Author(s): 竹中克斗,下田和哉,赤司浩一, (編集委員会編集)
  • Publisher: 南江堂
• [Book] 原発性骨髄線維症の診断と治療,白血病・リンパ腫・骨髄腫-今日の診断と治療 (2011)
  • Author(s): 北中明,下田和哉, (木崎昌弘編)
  • Publisher: 中外医学社
• [Book] 白血病・リンパ腫・骨髄腫－今日の診断と治療 (2011)
  • Author(s): 北中明
  • Total Pages: 544
  • Publisher: 中外医学社
• [Book] Annual Review 血液 2012 (2011)
  • Author(s): 北中明
  • Total Pages: 266
  • Publisher: 中外医学社